pdf File DDM.Grand.Rounds.Final.for.AUCD.pdf (2,077KB) [download]

Archived Recording
In order to view the webinar presentation, please click on the webinar icon below.

Wednesday, March 21, 2012
2:00pm EST - 3:00pm EST


During this webinar, the Southeast Regional Consortium and AUCD welcome Drs. Veenstra Vander-Weele and Warren to present results from their recent AHRQ commissioned comparative effectiveness report prepared by the Vanderbilt Evidence-based Practice Center entitled, ' Therapies for Children with Autism Spectrum Disorders.' 

This event will include a presentation of data from the review regarding the strength of existing evidence concerning early intensive behavioral and developmental interventions as well as medical (e.g. nutritional, pharmacological, etc.) interventions.  They will also present information regarding the current state of the literature, specific methodological strengths and concerns, as well as future directions for impactful research in these areas.

Webinar Objectives

  1. Discuss the current state of the ASD intervention literature as well as gaps in science revealed by the systematic review. 
  2. Review the strength of evidence for available intensive behavioral and developmental interventions for children with ASD.
  3. Review the strength of evidence for available pharmacological interventions for children with ASD.


Jeremy M. Veenstra-VanderWeele, M.D.

Assistant Professor of Psychiatry; Assistant Professor of Pediatrics; Assistant Professor of Pharmacology; Director, The Fragile X Treatment Research Program

Dr. Veenstra-VanderWeele is a child psychiatrist whose current research involves development of mouse models of autism by introducing knock-in mutations in the seretonin transporter gene. His efforts also focus on the creation and analysis of novel transgenic strains of mice allowing him to examine the impact of SERT variants on brain development, neurochemisty, and behavior.  Dr. Veenstra VanderWeele's is also involved in several clinical trials focusing on identification and rigourous application of novel therapeutic agents to treat impairments associated with autism spectrum disorders and related neurodevelopmental disabilities.

Zachary Warren, Ph.D.

Assistant Professor of Pediatrics, Division of Developmental Medicine; Assistant Professor of Psychiatry; Director, Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders (TRIAD); Director, Autism Clinical Services and Vanderbilt LEND faculty member.

Zachary Warren is a clinical psychologist who has worked in the field of autism and related disability for over a decade.  As director of TRIAD, Zachary Warren leads the autism evaluation and diagnostic clinics within the Department of Pediatrics, Division of Developmental Medicine, and he provides oversight of TRIAD Outreach and Training. In collaboration with colleagues across campus and at the VKC, Warren has developed and implemented plans for more streamlined recruitment and a centralized autism database, and he and colleagues are developing an autism-focused postdoctoral training program for psychologists. Warren facilitates communication and community-building activities for autism-related clinical and research activities within VKC TRIAD, UCEDD, LEND, and IDDRC programs and with faculty in Pediatrics, Psychiatry, Special Education, Psychology, and Hearing and Speech Sciences.  He has an active program of independent and collaborative research focused on enhancing our understanding of the developmental pathways and earliest core features of ASD, developing transformative methodologies for detection and treatment, and translating our knowledge of ASD intervention science into meaningful, and hopefully more optimal, systems of care for families and children with the disorder.    

This Webinar is in part made possible with support from The Maternal and Child Health Bureau (MCHB).